New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population

Christopher T. Campbell, Rachael McCaleb, Kalen B. Manasco

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Objective: To review the current literature on inhaled antibiotic therapies currently in clinical trials for cystic fibrosis (CF) patients. Data Sources: A literature search was performed using PubMed (1975 to September 2015), International Pharmaceutical Abstracts (1970 to September 2015), and MEDLINE (1946 to September 2015) to identify studies for inclusion. The following search terms were used: cystic fibrosis, inhaled amikacin, inhaled liposomal amikacin, inhaled vancomycin, and/or inhaled levofloxacin. Study Selection and Data Extraction: All English-language phase II to III studies evaluating efficacy and/or safety, case reports, and retrospective studies of inhaled amikacin, inhaled vancomycin, and inhaled levofloxacin in CF patients were included. Data Synthesis: Currently available inhaled antibiotics, tobramycin and aztreonam, have demonstrated improvement in respiratory function of CF patients. Newer agents have shown potentially similar efficacy, with improvement in ease of use. Limited data suggest that inhaled liposomal amikacin and levofloxacin are both noninferior to tobramycin in terms of improvements in respiratory function. Inhaled levofloxacin has a lower rate of hospitalizations secondary to respiratory exacerbations and a reduction in the Pseudomonas aeruginosa sputum density compared with inhaled tobramycin. Inhaled vancomycin use has been documented in case reports and 2 small retrospective eradication trials, although data are limited to support its use. Conclusions: The horizon of inhaled antibiotic choices for CF patients is promising. The introduction of different drug classes and formulations to treat resistant Gram-negative and Gram-positive organisms increases the number of options for patients for both eradication and treatment of chronic colonization.

Original languageEnglish (US)
Pages (from-to)133-140
Number of pages8
JournalAnnals of Pharmacotherapy
Volume50
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Levofloxacin
Cystic Fibrosis
Amikacin
Tobramycin
Vancomycin
Population
Anti-Bacterial Agents
Aztreonam
Drug Compounding
Information Storage and Retrieval
Sputum
PubMed
MEDLINE
Pseudomonas aeruginosa
Hospitalization
Language
Retrospective Studies
Clinical Trials
Safety
Therapeutics

Keywords

  • amikacin
  • cystic fibrosis
  • inhaled antibiotic
  • levofloxacin
  • vancomycin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population. / Campbell, Christopher T.; McCaleb, Rachael; Manasco, Kalen B.

In: Annals of Pharmacotherapy, Vol. 50, No. 2, 01.02.2016, p. 133-140.

Research output: Contribution to journalReview article

Campbell, Christopher T. ; McCaleb, Rachael ; Manasco, Kalen B. / New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population. In: Annals of Pharmacotherapy. 2016 ; Vol. 50, No. 2. pp. 133-140.
@article{1b2bc89e2532430a9791333f6bb147d2,
title = "New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population",
abstract = "Objective: To review the current literature on inhaled antibiotic therapies currently in clinical trials for cystic fibrosis (CF) patients. Data Sources: A literature search was performed using PubMed (1975 to September 2015), International Pharmaceutical Abstracts (1970 to September 2015), and MEDLINE (1946 to September 2015) to identify studies for inclusion. The following search terms were used: cystic fibrosis, inhaled amikacin, inhaled liposomal amikacin, inhaled vancomycin, and/or inhaled levofloxacin. Study Selection and Data Extraction: All English-language phase II to III studies evaluating efficacy and/or safety, case reports, and retrospective studies of inhaled amikacin, inhaled vancomycin, and inhaled levofloxacin in CF patients were included. Data Synthesis: Currently available inhaled antibiotics, tobramycin and aztreonam, have demonstrated improvement in respiratory function of CF patients. Newer agents have shown potentially similar efficacy, with improvement in ease of use. Limited data suggest that inhaled liposomal amikacin and levofloxacin are both noninferior to tobramycin in terms of improvements in respiratory function. Inhaled levofloxacin has a lower rate of hospitalizations secondary to respiratory exacerbations and a reduction in the Pseudomonas aeruginosa sputum density compared with inhaled tobramycin. Inhaled vancomycin use has been documented in case reports and 2 small retrospective eradication trials, although data are limited to support its use. Conclusions: The horizon of inhaled antibiotic choices for CF patients is promising. The introduction of different drug classes and formulations to treat resistant Gram-negative and Gram-positive organisms increases the number of options for patients for both eradication and treatment of chronic colonization.",
keywords = "amikacin, cystic fibrosis, inhaled antibiotic, levofloxacin, vancomycin",
author = "Campbell, {Christopher T.} and Rachael McCaleb and Manasco, {Kalen B.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1177/1060028015621916",
language = "English (US)",
volume = "50",
pages = "133--140",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "2",

}

TY - JOUR

T1 - New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population

AU - Campbell, Christopher T.

AU - McCaleb, Rachael

AU - Manasco, Kalen B.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective: To review the current literature on inhaled antibiotic therapies currently in clinical trials for cystic fibrosis (CF) patients. Data Sources: A literature search was performed using PubMed (1975 to September 2015), International Pharmaceutical Abstracts (1970 to September 2015), and MEDLINE (1946 to September 2015) to identify studies for inclusion. The following search terms were used: cystic fibrosis, inhaled amikacin, inhaled liposomal amikacin, inhaled vancomycin, and/or inhaled levofloxacin. Study Selection and Data Extraction: All English-language phase II to III studies evaluating efficacy and/or safety, case reports, and retrospective studies of inhaled amikacin, inhaled vancomycin, and inhaled levofloxacin in CF patients were included. Data Synthesis: Currently available inhaled antibiotics, tobramycin and aztreonam, have demonstrated improvement in respiratory function of CF patients. Newer agents have shown potentially similar efficacy, with improvement in ease of use. Limited data suggest that inhaled liposomal amikacin and levofloxacin are both noninferior to tobramycin in terms of improvements in respiratory function. Inhaled levofloxacin has a lower rate of hospitalizations secondary to respiratory exacerbations and a reduction in the Pseudomonas aeruginosa sputum density compared with inhaled tobramycin. Inhaled vancomycin use has been documented in case reports and 2 small retrospective eradication trials, although data are limited to support its use. Conclusions: The horizon of inhaled antibiotic choices for CF patients is promising. The introduction of different drug classes and formulations to treat resistant Gram-negative and Gram-positive organisms increases the number of options for patients for both eradication and treatment of chronic colonization.

AB - Objective: To review the current literature on inhaled antibiotic therapies currently in clinical trials for cystic fibrosis (CF) patients. Data Sources: A literature search was performed using PubMed (1975 to September 2015), International Pharmaceutical Abstracts (1970 to September 2015), and MEDLINE (1946 to September 2015) to identify studies for inclusion. The following search terms were used: cystic fibrosis, inhaled amikacin, inhaled liposomal amikacin, inhaled vancomycin, and/or inhaled levofloxacin. Study Selection and Data Extraction: All English-language phase II to III studies evaluating efficacy and/or safety, case reports, and retrospective studies of inhaled amikacin, inhaled vancomycin, and inhaled levofloxacin in CF patients were included. Data Synthesis: Currently available inhaled antibiotics, tobramycin and aztreonam, have demonstrated improvement in respiratory function of CF patients. Newer agents have shown potentially similar efficacy, with improvement in ease of use. Limited data suggest that inhaled liposomal amikacin and levofloxacin are both noninferior to tobramycin in terms of improvements in respiratory function. Inhaled levofloxacin has a lower rate of hospitalizations secondary to respiratory exacerbations and a reduction in the Pseudomonas aeruginosa sputum density compared with inhaled tobramycin. Inhaled vancomycin use has been documented in case reports and 2 small retrospective eradication trials, although data are limited to support its use. Conclusions: The horizon of inhaled antibiotic choices for CF patients is promising. The introduction of different drug classes and formulations to treat resistant Gram-negative and Gram-positive organisms increases the number of options for patients for both eradication and treatment of chronic colonization.

KW - amikacin

KW - cystic fibrosis

KW - inhaled antibiotic

KW - levofloxacin

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84954350106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954350106&partnerID=8YFLogxK

U2 - 10.1177/1060028015621916

DO - 10.1177/1060028015621916

M3 - Review article

C2 - 26692274

AN - SCOPUS:84954350106

VL - 50

SP - 133

EP - 140

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 2

ER -